Mark R Rigby MD , PhD, FAAP, FCCM

Summary

• Dr. Mark Rigby, based in Philadelphia, PA, is a specialist in research with expertise in immunotherapy and clinical research. He earned his MD from the University of Massachusetts Medical School in 1997, completed his residency in Pediatrics, and a fellowship in Pediatric Critical Care Medicine at Johns Hopkins University. His career includes leadership roles in immunology and clinical development at Teva Pharmaceuticals, Janssen Pharmaceuticals, and ProventionBio, and AnaptysBio/First Tracks Bio as well as academic positions at Emory University and Indiana University. Dr. Rigby has authored several publications in esteemed journals and has contributed to multiple clinical trials related to type 1 diabetes and pediatric care and helped develop the Phase 3 clinical trial of teplizumab that support the first immune therapy approved for new onset T1D. He has been recognized by the Society for Pediatric Research and is a Fellow of the American College of Critical Care Medicine.